http://www.novartis.com 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml 2009-12-03T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1358846.shtml Basel, December 3, 2009 - Novartis announced today that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). 2009-10-19T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1348153.shtml Basel, October 19, 2009 - Novartis has received a Complete Response letter from the US Food and Drug Administration (FDA) as part of the US regulatory review for QAB149 (indacaterol), an investigational once-daily bronchodilator for the treatment of adult patients with chronic obstructive pulmonary disease (COPD). 2009-09-25T17:20:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1343682.shtml Basel, September 25, 2009 - Novartis has received a positive opinion recommending European Union (EU) approval of QAB149 (indacaterol) for maintenance bronchodilator treatment in adult patients with chronic obstructive pulmonary disease (COPD). When approved, QAB149 and its device, Concept-1, will be known as Onbrez® Breezhaler®[§]. 2009-09-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1341238.shtml Disclaimer 2009-08-24T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1336542.shtml About Novartis 2009-07-16T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1329090.shtml Basel, July 16, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: I am pleased that our pharmaceuticals business continues to deliver double-digit underlying growth, driven by the strong momentum of our recently launched products. Our pipeline continues to deliver a steady stream of innovative medicines. In the first six months of 2009 we have introduced our new anti-cancer therapy Afinitor in the US and gained first approval for llaris as a new biologic therapy for auto-inflammatory diseases. We are advancing well in our efforts to rapidly produce and commercialize a vaccine against the H1N1 virus, with clinical trials set to begin in July. We continue to expect record underlying results in constant currencies based on innovation and productivity initiatives. 2009-05-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1316055.shtml Basel, May 19, 2009 - Novartis has assumed exclusive worldwide rights to develop and commercialize QMF149, a fixed-combination of its investigational QAB149 (indacaterol) with Schering-Plough Corporation's inhaled corticosteroid mometasone, in changes announced today to the companies' collaboration to develop fixed-dose combination respiratory therapies. 2008-10-08T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1257684.shtml Basel, October 8, 2008 - An early proof-of-concept study presented today shows promising results for imatinib in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. 2008-10-07T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1257283.shtml Basel, October 7, 2008 - New Phase II data show that NVA237 (glycopyrronium bromide), a novel inhaled long-acting muscarinic antagonist (LAMA), provides sustained 24-hour bronchodilation in patients with moderate-to-severe COPD[1]. NVA237 showed similar efficacy and duration of action to tiotropium with potentially a more rapid onset of action[1]. 2008-10-06T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1257049.shtml Basel, October 6, 2008 - A new clinical study shows that Xolair® (omalizumab), an innovative treatment for allergic asthma in adolescents and adults, significantly reduced asthma attacks (or 'exacerbations') in children aged six to 11 years with uncontrolled moderate-to-severe persistent allergic asthma[1]. 2009-07-16T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2009/1329097.shtml Bâle, le 16 juillet 2009 - En commentant les résultats, le DrDaniel Vasella, Président et Administrateur délégué de Novartis a déclaré: «Je suis heureux de voir que nos activités pharmaceutiques continuent de progresser au rythme d'une croissance sous-jacente à deux chiffres, sous la forte impulsion des produits lancés récemment. Tandis que notre pipeline émet un flux continu de médicaments innovants. Au cours des six premiers mois de 2009, nous avons lancé Afinitor, notre nouveau traitement anticancer aux Etats-Unis où nous avons également obtenu une première homologation pour Ilaris, un nouveau traitement biologique pour un groupe de maladies auto-inflammatoires. Nous avançons rapidement vers la production et la commercialisation d'un vaccin contre le virus H1N1, dont les essais cliniques commenceront en juillet. Nous prévoyons toujours de réaliser des résultats sous-jacents records en monnaies constantes, grâce à l'innovation et aux gains de productivité». 2009-07-16T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1329092.shtml Erstes Halbjahr